Advertisement

 

 

Ovarian cancer.

Ovarian cancer.
Author Information (click to view)

Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY,


Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY, (click to view)

Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Nature reviews. Disease primers 2016 08 252() 16061 doi 10.1038/nrdp.2016.61

Abstract

Ovarian cancer is not a single disease and can be subdivided into at least five different histological subtypes that have different identifiable risk factors, cells of origin, molecular compositions, clinical features and treatments. Ovarian cancer is a global problem, is typically diagnosed at a late stage and has no effective screening strategy. Standard treatments for newly diagnosed cancer consist of cytoreductive surgery and platinum-based chemotherapy. In recurrent cancer, chemotherapy, anti-angiogenic agents and poly(ADP-ribose) polymerase inhibitors are used, and immunological therapies are currently being tested. High-grade serous carcinoma (HGSC) is the most commonly diagnosed form of ovarian cancer and at diagnosis is typically very responsive to platinum-based chemotherapy. However, in addition to the other histologies, HGSCs frequently relapse and become increasingly resistant to chemotherapy. Consequently, understanding the mechanisms underlying platinum resistance and finding ways to overcome them are active areas of study in ovarian cancer. Substantial progress has been made in identifying genes that are associated with a high risk of ovarian cancer (such as BRCA1 and BRCA2), as well as a precursor lesion of HGSC called serous tubal intraepithelial carcinoma, which holds promise for identifying individuals at high risk of developing the disease and for developing prevention strategies.

Submit a Comment

Your email address will not be published. Required fields are marked *

one × 4 =

[ HIDE/SHOW ]